Serotonin signaling: a new player and therapeutic target beyond Long-haul coronavirus disease
Serotonin signaling: a new player and therapeutic target beyond Long-haul coronavirus disease
During the coronavirus disease 2019 (COVID-19) pandemic, a subset of individuals continues to suffer from symptoms including fatigue, post-exertional malaise, dyspnea, bone loss, and memory and neurocognitive dysfunction for months and even years after infection. This clinical phenomenon has been labeled ‘Long-haul COVID’ or ‘post-acute sequelae of COVID-19 (PASC)’; however, the underlying pathophysiological mechanisms remain unclear. In a recent study published in Cell, Wong et al. revealed that viral infection and type I interferon-driven reduction of peripheral serotonin impaired hippocampal responses and short-term memory through vagal neurons in patients with PASC. Therefore, the study provided novel insights into how serotonin links persistent viral inflammation with the neurocognitive symptoms of Long-haul COVID and actionable therapeutic targets for patients with PASC.
COVID-19 / neurocognitive disorders / serotonin
1 | AC Wong, AS Devason, IC Umana, et al. Serotonin reduction in post-acute sequelae of viral infection. Cell. 2023;186(22):4851-4867. e20. |
2 | W Qiao, HE Lau, H Xie, et al. SARS-CoV-2 infection induces inflammatory bone loss in golden Syrian hamsters. Nat Commun. 2022;13(1):2539. |
3 | E Sugisawa, Y Takayama, N Takemura, et al. RNA sensing by Gut Piezo1 Is essential for systemic serotonin synthesis. Cell. 2020;182(3):609-624. e21. |
4 | M De Giovanni, H Tam, C Valet, Y Xu, MR Looney, JG Cyster. GPR35 promotes neutrophil recruitment in response to serotonin metabolite 5-HIAA. Cell. 2022;185(6):1103-1104. |
5 | X Wang, SQ Fu, X Yuan, et al. A GAPDH serotonylation system couples CD8(+) T cell glycolytic metabolism to antitumor immunity. Mol Cell. 2024;84(4):760-775. e7. |
/
〈 | 〉 |